Dr. Anuja Java, MD
Nephrology (Kidney) (Nephrology Physician)
4921 Parkview Pl, Div Im Nephrology, Ste 5c
Saint Louis, MO 63110
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 193
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
MO license 2009001291
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 193
- Services billed
- 478
- Patients’ average age
- 61
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 133 | 53 |
| Established patient office or other outpatient visit, 40-54 minutes | 102 | 94 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 68 | 30 |
| Urinalysis, manual test | 58 | 43 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 28 | 27 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 22 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 27 payments worth $78,221 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $59,434 |
|---|---|
| Novartis Pharmaceuticals Corporation | $15,289 |
| Apellis Pharmaceuticals, Inc. | $3,252 |
| Calliditas Therapeutics US Inc. | $246 |
| Consulting Fee | $41,273 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $20,435 |
| Travel and Lodging | $15,658 |
| Food and Beverage | $855 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) SOLIRIS · Rare Disease Company’s descriptionSpeaker Fee | $20,435 |
| Alexion Pharmaceuticals, Inc. Jun 26, 2025 | Consulting Fee | $16,080 |
| Alexion Pharmaceuticals, Inc. May 15, 2025 | Travel and Lodging SOLIRIS · Rare Disease · travel to Tokyo, Japan · in-kind Company’s descriptionSpeaker Expenses | $12,395 |
| Novartis Pharmaceuticals Corporation Oct 22, 2025 | Consulting Fee Fabhalta · Immunology | $10,000 |
| Alexion Pharmaceuticals, Inc. Dec 1, 2025 | Consulting Fee | $5,695 |
| Apellis Pharmaceuticals, Inc. Aug 4, 2025 | Consulting Fee | $3,068 |
| Novartis Pharmaceuticals Corporation Sep 18, 2025 | Consulting Fee | $3,000 |
| Alexion Pharmaceuticals, Inc. Dec 10, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $2,680 |
| Alexion Pharmaceuticals, Inc. May 18, 2025 | Travel and Lodging SOLIRIS · Rare Disease · travel to Tokyo, Japan · in-kind Company’s descriptionSpeaker Expenses | $1,436 |
| Novartis Pharmaceuticals Corporation Oct 2, 2025 | Travel and Lodging travel to Morristown, NJ · in-kind | $852 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Dec 10, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $2,680 |
| Novartis Pharmaceuticals Corporation Dec 8, 2025 | Consulting Fee Fabhalta · Immunology | $750 |
| Alexion Pharmaceuticals, Inc. Dec 1, 2025 | Consulting Fee | $5,695 |
| Novartis Pharmaceuticals Corporation Oct 29, 2025 | Travel and Lodging Fabhalta · Immunology · travel to East Hanover, NJ | $88.85 |
| Novartis Pharmaceuticals Corporation Oct 22, 2025 | Consulting Fee Fabhalta · Immunology | $10,000 |
| Novartis Pharmaceuticals Corporation Oct 3, 2025 | Travel and Lodging Fabhalta · Immunology · travel to East Hanover, NJ · in-kind | $297 |
| Novartis Pharmaceuticals Corporation Oct 3, 2025 | Travel and Lodging Fabhalta · Immunology · travel to East Hanover, NJ | $114 |
| Novartis Pharmaceuticals Corporation Oct 2, 2025 | Travel and Lodging travel to Morristown, NJ · in-kind | $852 |
| Novartis Pharmaceuticals Corporation Sep 18, 2025 | Consulting Fee | $3,000 |
| Apellis Pharmaceuticals, Inc. Aug 4, 2025 | Consulting Fee | $3,068 |
| Alexion Pharmaceuticals, Inc. Jun 26, 2025 | Consulting Fee | $16,080 |
| Alexion Pharmaceuticals, Inc. Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) SOLIRIS · Rare Disease Company’s descriptionSpeaker Fee | $20,435 |
| Alexion Pharmaceuticals, Inc. May 18, 2025 | Travel and Lodging SOLIRIS · Rare Disease · travel to Tokyo, Japan · in-kind Company’s descriptionSpeaker Expenses | $1,436 |
| Alexion Pharmaceuticals, Inc. May 16, 2025 | Travel and Lodging SOLIRIS · Rare Disease · travel to Tokyo, Japan · in-kind Company’s descriptionSpeaker Expenses | $476 |
| Alexion Pharmaceuticals, Inc. May 15, 2025 | Travel and Lodging SOLIRIS · Rare Disease · travel to Tokyo, Japan · in-kind Company’s descriptionSpeaker Expenses | $12,395 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $17,974 in research payments for these studies, mostly to the institutions running them.
- A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult aHUS Patients Who Are Naive to Complement Inhibitor Therapy
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.